![CMS-medicare-AHA-comment](/sites/default/files/2018-05/CMS-medicare-AHA-comment.jpg)
Gilead Sciences said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement, Gilead said the inhaled version could better target respiratory infections and limit systemic exposure to remdesivir and be accessible to non-hospitalized patients.